Becton, Dickinson and Company

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, SRTOY has a market cap of 216.08B. Regarding current trading prices, BDXA is priced at $59.24, while SRTOY trades at $22.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas SRTOY's P/E ratio is 92.54. In terms of profitability, BDXA's ROE is +0.06%, compared to SRTOY's ROE of +0.05%. Regarding short-term risk, BDXA is more volatile compared to SRTOY. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, ISRG has a market cap of 190.61B. Regarding current trading prices, BDXA is priced at $59.24, while ISRG trades at $531.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas ISRG's P/E ratio is 77.87. In terms of profitability, BDXA's ROE is +0.06%, compared to ISRG's ROE of +0.16%. Regarding short-term risk, BDXA is more volatile compared to ISRG. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, ESLOF has a market cap of 132.62B. Regarding current trading prices, BDXA is priced at $59.24, while ESLOF trades at $290.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas ESLOF's P/E ratio is 49.98. In terms of profitability, BDXA's ROE is +0.06%, compared to ESLOF's ROE of +0.06%. Regarding short-term risk, BDXA is more volatile compared to ESLOF. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, ESLOY has a market cap of 132.32B. Regarding current trading prices, BDXA is priced at $59.24, while ESLOY trades at $145.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas ESLOY's P/E ratio is 50.16. In terms of profitability, BDXA's ROE is +0.06%, compared to ESLOY's ROE of +0.06%. Regarding short-term risk, BDXA is more volatile compared to ESLOY. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, MECNY has a market cap of 107.62B. Regarding current trading prices, BDXA is priced at $59.24, while MECNY trades at $88.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas MECNY's P/E ratio is N/A. In terms of profitability, BDXA's ROE is +0.06%, compared to MECNY's ROE of +0.02%. Regarding short-term risk, BDXA is more volatile compared to MECNY. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, SOAGY has a market cap of 83.32B. Regarding current trading prices, BDXA is priced at $59.24, while SOAGY trades at $53.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas SOAGY's P/E ratio is 173.43. In terms of profitability, BDXA's ROE is +0.06%, compared to SOAGY's ROE of +0.05%. Regarding short-term risk, BDXA is more volatile compared to SOAGY. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, SSSGY has a market cap of 82.17B. Regarding current trading prices, BDXA is priced at $59.24, while SSSGY trades at $39.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas SSSGY's P/E ratio is 125.81. In terms of profitability, BDXA's ROE is +0.06%, compared to SSSGY's ROE of +0.05%. Regarding short-term risk, BDXA is more volatile compared to SSSGY. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, ALC has a market cap of 48.18B. Regarding current trading prices, BDXA is priced at $59.24, while ALC trades at $97.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas ALC's P/E ratio is 47.52. In terms of profitability, BDXA's ROE is +0.06%, compared to ALC's ROE of +0.06%. Regarding short-term risk, BDXA is more volatile compared to ALC. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, BDX has a market cap of 47.91B. Regarding current trading prices, BDXA is priced at $59.24, while BDX trades at $166.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas BDX's P/E ratio is 32.34. In terms of profitability, BDXA's ROE is +0.06%, compared to BDX's ROE of +0.06%. Regarding short-term risk, BDXA is more volatile compared to BDX. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, HOCPF has a market cap of 44.66B. Regarding current trading prices, BDXA is priced at $59.24, while HOCPF trades at $130.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas HOCPF's P/E ratio is 31.32. In terms of profitability, BDXA's ROE is +0.06%, compared to HOCPF's ROE of +0.15%. Regarding short-term risk, BDXA is more volatile compared to HOCPF. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, HOCPY has a market cap of 43.48B. Regarding current trading prices, BDXA is priced at $59.24, while HOCPY trades at $126.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas HOCPY's P/E ratio is 31.56. In terms of profitability, BDXA's ROE is +0.06%, compared to HOCPY's ROE of +0.15%. Regarding short-term risk, BDXA is more volatile compared to HOCPY. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, RMD has a market cap of 35.29B. Regarding current trading prices, BDXA is priced at $59.24, while RMD trades at $240.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas RMD's P/E ratio is 28.45. In terms of profitability, BDXA's ROE is +0.06%, compared to RMD's ROE of +0.25%. Regarding short-term risk, BDXA is more volatile compared to RMD. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, TRUMF has a market cap of 29.18B. Regarding current trading prices, BDXA is priced at $59.24, while TRUMF trades at $19.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas TRUMF's P/E ratio is 33.77. In terms of profitability, BDXA's ROE is +0.06%, compared to TRUMF's ROE of +0.07%. Regarding short-term risk, BDXA is less volatile compared to TRUMF. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, TRUMY has a market cap of 29.10B. Regarding current trading prices, BDXA is priced at $59.24, while TRUMY trades at $19.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas TRUMY's P/E ratio is 33.44. In terms of profitability, BDXA's ROE is +0.06%, compared to TRUMY's ROE of +0.07%. Regarding short-term risk, BDXA is more volatile compared to TRUMY. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, CLPBY has a market cap of 24.37B. Regarding current trading prices, BDXA is priced at $59.24, while CLPBY trades at $10.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas CLPBY's P/E ratio is 33.78. In terms of profitability, BDXA's ROE is +0.06%, compared to CLPBY's ROE of +0.30%. Regarding short-term risk, BDXA is less volatile compared to CLPBY. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, CLPBF has a market cap of 23.91B. Regarding current trading prices, BDXA is priced at $59.24, while CLPBF trades at $106.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas CLPBF's P/E ratio is 32.29. In terms of profitability, BDXA's ROE is +0.06%, compared to CLPBF's ROE of +0.30%. Regarding short-term risk, BDXA is more volatile compared to CLPBF. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, SDMHF has a market cap of 23.53B. Regarding current trading prices, BDXA is priced at $59.24, while SDMHF trades at $241.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas SDMHF's P/E ratio is 101.60. In terms of profitability, BDXA's ROE is +0.06%, compared to SDMHF's ROE of +0.05%. Regarding short-term risk, BDXA is more volatile compared to SDMHF. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, RSMDF has a market cap of 22.50B. Regarding current trading prices, BDXA is priced at $59.24, while RSMDF trades at $14.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas RSMDF's P/E ratio is 16.55. In terms of profitability, BDXA's ROE is +0.06%, compared to RSMDF's ROE of +0.25%. Regarding short-term risk, BDXA is more volatile compared to RSMDF. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, SUVPF has a market cap of 22.02B. Regarding current trading prices, BDXA is priced at $59.24, while SUVPF trades at $263.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas SUVPF's P/E ratio is 167.58. In terms of profitability, BDXA's ROE is +0.06%, compared to SUVPF's ROE of +0.05%. Regarding short-term risk, BDXA is more volatile compared to SUVPF. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, SAUHF has a market cap of 20.11B. Regarding current trading prices, BDXA is priced at $59.24, while SAUHF trades at $126.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas SAUHF's P/E ratio is 36.34. In terms of profitability, BDXA's ROE is +0.06%, compared to SAUHF's ROE of +0.14%. Regarding short-term risk, BDXA is more volatile compared to SAUHF. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, SAUHY has a market cap of 20.07B. Regarding current trading prices, BDXA is priced at $59.24, while SAUHY trades at $12.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas SAUHY's P/E ratio is 35.97. In terms of profitability, BDXA's ROE is +0.06%, compared to SAUHY's ROE of +0.14%. Regarding short-term risk, BDXA is more volatile compared to SAUHY. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, COO has a market cap of 16.31B. Regarding current trading prices, BDXA is priced at $59.24, while COO trades at $81.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas COO's P/E ratio is 39.41. In terms of profitability, BDXA's ROE is +0.06%, compared to COO's ROE of +0.05%. Regarding short-term risk, BDXA is more volatile compared to COO. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, SARTF has a market cap of 16.13B. Regarding current trading prices, BDXA is priced at $59.24, while SARTF trades at $210.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas SARTF's P/E ratio is 134.91. In terms of profitability, BDXA's ROE is +0.06%, compared to SARTF's ROE of +0.05%. Regarding short-term risk, BDXA is more volatile compared to SARTF. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, BAX has a market cap of 15.61B. Regarding current trading prices, BDXA is priced at $59.24, while BAX trades at $30.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas BAX's P/E ratio is -52.48. In terms of profitability, BDXA's ROE is +0.06%, compared to BAX's ROE of -0.05%. Regarding short-term risk, BDXA is more volatile compared to BAX. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, WST has a market cap of 15.16B. Regarding current trading prices, BDXA is priced at $59.24, while WST trades at $210.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas WST's P/E ratio is 31.49. In terms of profitability, BDXA's ROE is +0.06%, compared to WST's ROE of +0.17%. Regarding short-term risk, BDXA is more volatile compared to WST. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, OCPNF has a market cap of 14.24B. Regarding current trading prices, BDXA is priced at $59.24, while OCPNF trades at $12.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas OCPNF's P/E ratio is 21.81. In terms of profitability, BDXA's ROE is +0.06%, compared to OCPNF's ROE of +0.10%. Regarding short-term risk, BDXA is less volatile compared to OCPNF. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, BDXB has a market cap of 13.69B. Regarding current trading prices, BDXA is priced at $59.24, while BDXB trades at $48.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas BDXB's P/E ratio is 7.60. In terms of profitability, BDXA's ROE is +0.06%, compared to BDXB's ROE of +0.06%. Regarding short-term risk, BDXA is more volatile compared to BDXB. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, HOLX has a market cap of 11.83B. Regarding current trading prices, BDXA is priced at $59.24, while HOLX trades at $52.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas HOLX's P/E ratio is 22.16. In terms of profitability, BDXA's ROE is +0.06%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, BDXA is more volatile compared to HOLX. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, SSMXY has a market cap of 11.63B. Regarding current trading prices, BDXA is priced at $59.24, while SSMXY trades at $18.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas SSMXY's P/E ratio is 28.69. In terms of profitability, BDXA's ROE is +0.06%, compared to SSMXY's ROE of +0.09%. Regarding short-term risk, BDXA is more volatile compared to SSMXY. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, FSPKF has a market cap of 10.76B. Regarding current trading prices, BDXA is priced at $59.24, while FSPKF trades at $18.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas FSPKF's P/E ratio is 141.23. In terms of profitability, BDXA's ROE is +0.06%, compared to FSPKF's ROE of +0.10%. Regarding short-term risk, BDXA is less volatile compared to FSPKF. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, SSMXF has a market cap of 10.13B. Regarding current trading prices, BDXA is priced at $59.24, while SSMXF trades at $16.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas SSMXF's P/E ratio is 24.98. In terms of profitability, BDXA's ROE is +0.06%, compared to SSMXF's ROE of +0.09%. Regarding short-term risk, BDXA is more volatile compared to SSMXF. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, ATR has a market cap of 9.99B. Regarding current trading prices, BDXA is priced at $59.24, while ATR trades at $151.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas ATR's P/E ratio is 27.69. In terms of profitability, BDXA's ROE is +0.06%, compared to ATR's ROE of +0.15%. Regarding short-term risk, BDXA is more volatile compared to ATR. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, MASI has a market cap of 8.80B. Regarding current trading prices, BDXA is priced at $59.24, while MASI trades at $162.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas MASI's P/E ratio is -28.47. In terms of profitability, BDXA's ROE is +0.06%, compared to MASI's ROE of -0.23%. Regarding short-term risk, BDXA is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, RGEN has a market cap of 7.92B. Regarding current trading prices, BDXA is priced at $59.24, while RGEN trades at $140.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas RGEN's P/E ratio is -335.52. In terms of profitability, BDXA's ROE is +0.06%, compared to RGEN's ROE of -0.01%. Regarding short-term risk, BDXA is more volatile compared to RGEN. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, CNVVY has a market cap of 7.31B. Regarding current trading prices, BDXA is priced at $59.24, while CNVVY trades at $14.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas CNVVY's P/E ratio is 38.65. In terms of profitability, BDXA's ROE is +0.06%, compared to CNVVY's ROE of +0.16%. Regarding short-term risk, BDXA is more volatile compared to CNVVY. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, CNVVF has a market cap of 6.12B. Regarding current trading prices, BDXA is priced at $59.24, while CNVVF trades at $3.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas CNVVF's P/E ratio is 33.33. In terms of profitability, BDXA's ROE is +0.06%, compared to CNVVF's ROE of +0.16%. Regarding short-term risk, BDXA is more volatile compared to CNVVF. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, STVN has a market cap of 6.04B. Regarding current trading prices, BDXA is priced at $59.24, while STVN trades at $22.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas STVN's P/E ratio is 45.14. In terms of profitability, BDXA's ROE is +0.06%, compared to STVN's ROE of +0.09%. Regarding short-term risk, BDXA is more volatile compared to STVN. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, CZMWF has a market cap of 6.00B. Regarding current trading prices, BDXA is priced at $59.24, while CZMWF trades at $68.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas CZMWF's P/E ratio is 34.29. In terms of profitability, BDXA's ROE is +0.06%, compared to CZMWF's ROE of +0.07%. Regarding short-term risk, BDXA is more volatile compared to CZMWF. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, CZMWY has a market cap of 5.88B. Regarding current trading prices, BDXA is priced at $59.24, while CZMWY trades at $67.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas CZMWY's P/E ratio is 33.43. In terms of profitability, BDXA's ROE is +0.06%, compared to CZMWY's ROE of +0.07%. Regarding short-term risk, BDXA is more volatile compared to CZMWY. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, YPHDF has a market cap of 5.70B. Regarding current trading prices, BDXA is priced at $59.24, while YPHDF trades at $417.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas YPHDF's P/E ratio is 63.33. In terms of profitability, BDXA's ROE is +0.06%, compared to YPHDF's ROE of +0.13%. Regarding short-term risk, BDXA is less volatile compared to YPHDF. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, MMSI has a market cap of 5.55B. Regarding current trading prices, BDXA is priced at $59.24, while MMSI trades at $93.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas MMSI's P/E ratio is 46.28. In terms of profitability, BDXA's ROE is +0.06%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, BDXA is more volatile compared to MMSI. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, TFX has a market cap of 5.49B. Regarding current trading prices, BDXA is priced at $59.24, while TFX trades at $122.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas TFX's P/E ratio is 37.94. In terms of profitability, BDXA's ROE is +0.06%, compared to TFX's ROE of +0.03%. Regarding short-term risk, BDXA is more volatile compared to TFX. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, ADDLF has a market cap of 4.93B. Regarding current trading prices, BDXA is priced at $59.24, while ADDLF trades at $42.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas ADDLF's P/E ratio is 61.76. In terms of profitability, BDXA's ROE is +0.06%, compared to ADDLF's ROE of +0.06%. Regarding short-term risk, BDXA is less volatile compared to ADDLF. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, AHICF has a market cap of 4.39B. Regarding current trading prices, BDXA is priced at $59.24, while AHICF trades at $16.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas AHICF's P/E ratio is 34.40. In terms of profitability, BDXA's ROE is +0.06%, compared to AHICF's ROE of +0.07%. Regarding short-term risk, BDXA is more volatile compared to AHICF. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, BLCO has a market cap of 4.02B. Regarding current trading prices, BDXA is priced at $59.24, while BLCO trades at $11.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas BLCO's P/E ratio is -11.16. In terms of profitability, BDXA's ROE is +0.06%, compared to BLCO's ROE of -0.08%. Regarding short-term risk, BDXA is more volatile compared to BLCO. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, FLMNF has a market cap of 3.93B. Regarding current trading prices, BDXA is priced at $59.24, while FLMNF trades at $46.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas FLMNF's P/E ratio is 24.74. In terms of profitability, BDXA's ROE is +0.06%, compared to FLMNF's ROE of +0.15%. Regarding short-term risk, BDXA is more volatile compared to FLMNF. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, FLMNY has a market cap of 3.62B. Regarding current trading prices, BDXA is priced at $59.24, while FLMNY trades at $8.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas FLMNY's P/E ratio is 24.63. In terms of profitability, BDXA's ROE is +0.06%, compared to FLMNY's ROE of +0.15%. Regarding short-term risk, BDXA is more volatile compared to FLMNY. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, ICUI has a market cap of 3.35B. Regarding current trading prices, BDXA is priced at $59.24, while ICUI trades at $136.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas ICUI's P/E ratio is -28.16. In terms of profitability, BDXA's ROE is +0.06%, compared to ICUI's ROE of -0.06%. Regarding short-term risk, BDXA is more volatile compared to ICUI. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, HAE has a market cap of 3.14B. Regarding current trading prices, BDXA is priced at $59.24, while HAE trades at $62.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas HAE's P/E ratio is 25.29. In terms of profitability, BDXA's ROE is +0.06%, compared to HAE's ROE of +0.14%. Regarding short-term risk, BDXA is more volatile compared to HAE. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, SHWGY has a market cap of 3.00B. Regarding current trading prices, BDXA is priced at $59.24, while SHWGY trades at $2.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas SHWGY's P/E ratio is 11.52. In terms of profitability, BDXA's ROE is +0.06%, compared to SHWGY's ROE of +0.09%. Regarding short-term risk, BDXA is more volatile compared to SHWGY. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, SHWGF has a market cap of 2.98B. Regarding current trading prices, BDXA is priced at $59.24, while SHWGF trades at $0.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas SHWGF's P/E ratio is 11.00. In terms of profitability, BDXA's ROE is +0.06%, compared to SHWGF's ROE of +0.09%. Regarding short-term risk, BDXA is more volatile compared to SHWGF. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, XRAY has a market cap of 2.76B. Regarding current trading prices, BDXA is priced at $59.24, while XRAY trades at $13.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas XRAY's P/E ratio is -3.09. In terms of profitability, BDXA's ROE is +0.06%, compared to XRAY's ROE of -0.34%. Regarding short-term risk, BDXA is more volatile compared to XRAY. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, ANSLY has a market cap of 2.72B. Regarding current trading prices, BDXA is priced at $59.24, while ANSLY trades at $74.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas ANSLY's P/E ratio is 23.06. In terms of profitability, BDXA's ROE is +0.06%, compared to ANSLY's ROE of +0.04%. Regarding short-term risk, BDXA is more volatile compared to ANSLY. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, ANSLF has a market cap of 2.62B. Regarding current trading prices, BDXA is priced at $59.24, while ANSLF trades at $18.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas ANSLF's P/E ratio is 22.22. In terms of profitability, BDXA's ROE is +0.06%, compared to ANSLF's ROE of +0.06%. Regarding short-term risk, BDXA is more volatile compared to ANSLF. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, TCHBF has a market cap of 2.32B. Regarding current trading prices, BDXA is priced at $59.24, while TCHBF trades at $182.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas TCHBF's P/E ratio is 28.51. In terms of profitability, BDXA's ROE is +0.06%, compared to TCHBF's ROE of +0.07%. Regarding short-term risk, BDXA is less volatile compared to TCHBF. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, TCGGY has a market cap of 2.31B. Regarding current trading prices, BDXA is priced at $59.24, while TCGGY trades at $36.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas TCGGY's P/E ratio is 28.13. In terms of profitability, BDXA's ROE is +0.06%, compared to TCGGY's ROE of +0.07%. Regarding short-term risk, BDXA is more volatile compared to TCGGY. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, GRRMF has a market cap of 2.21B. Regarding current trading prices, BDXA is priced at $59.24, while GRRMF trades at $64.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas GRRMF's P/E ratio is 24.83. In terms of profitability, BDXA's ROE is +0.06%, compared to GRRMF's ROE of +0.05%. Regarding short-term risk, BDXA is less volatile compared to GRRMF. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, BOEUF has a market cap of 2.10B. Regarding current trading prices, BDXA is priced at $59.24, while BOEUF trades at $31.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas BOEUF's P/E ratio is 167.89. In terms of profitability, BDXA's ROE is +0.06%, compared to BOEUF's ROE of +0.18%. Regarding short-term risk, BDXA is more volatile compared to BOEUF. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, WRBY has a market cap of 2.07B. Regarding current trading prices, BDXA is priced at $59.24, while WRBY trades at $16.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas WRBY's P/E ratio is -99.79. In terms of profitability, BDXA's ROE is +0.06%, compared to WRBY's ROE of -0.06%. Regarding short-term risk, BDXA is more volatile compared to WRBY. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, NVCR has a market cap of 1.98B. Regarding current trading prices, BDXA is priced at $59.24, while NVCR trades at $17.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas NVCR's P/E ratio is -11.38. In terms of profitability, BDXA's ROE is +0.06%, compared to NVCR's ROE of -0.45%. Regarding short-term risk, BDXA is more volatile compared to NVCR. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, EKTAY has a market cap of 1.96B. Regarding current trading prices, BDXA is priced at $59.24, while EKTAY trades at $5.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas EKTAY's P/E ratio is 18.21. In terms of profitability, BDXA's ROE is +0.06%, compared to EKTAY's ROE of +0.10%. Regarding short-term risk, BDXA is more volatile compared to EKTAY. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, EKTAF has a market cap of 1.89B. Regarding current trading prices, BDXA is priced at $59.24, while EKTAF trades at $5.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas EKTAF's P/E ratio is 18.44. In terms of profitability, BDXA's ROE is +0.06%, compared to EKTAF's ROE of +0.10%. Regarding short-term risk, BDXA is more volatile compared to EKTAF. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, QDEL has a market cap of 1.87B. Regarding current trading prices, BDXA is priced at $59.24, while QDEL trades at $27.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas QDEL's P/E ratio is -0.91. In terms of profitability, BDXA's ROE is +0.06%, compared to QDEL's ROE of -0.64%. Regarding short-term risk, BDXA is more volatile compared to QDEL. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, LMAT has a market cap of 1.82B. Regarding current trading prices, BDXA is priced at $59.24, while LMAT trades at $80.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas LMAT's P/E ratio is 41.68. In terms of profitability, BDXA's ROE is +0.06%, compared to LMAT's ROE of +0.14%. Regarding short-term risk, BDXA is more volatile compared to LMAT. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, TGLVY has a market cap of 1.62B. Regarding current trading prices, BDXA is priced at $59.24, while TGLVY trades at $0.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas TGLVY's P/E ratio is 80.65. In terms of profitability, BDXA's ROE is +0.06%, compared to TGLVY's ROE of +0.02%. Regarding short-term risk, BDXA is more volatile compared to TGLVY. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, NPRRF has a market cap of 1.53B. Regarding current trading prices, BDXA is priced at $59.24, while NPRRF trades at $8.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas NPRRF's P/E ratio is 44.74. In terms of profitability, BDXA's ROE is +0.06%, compared to NPRRF's ROE of N/A. Regarding short-term risk, BDXA is more volatile compared to NPRRF. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, ATRC has a market cap of 1.44B. Regarding current trading prices, BDXA is priced at $59.24, while ATRC trades at $29.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas ATRC's P/E ratio is -35.86. In terms of profitability, BDXA's ROE is +0.06%, compared to ATRC's ROE of -0.08%. Regarding short-term risk, BDXA is more volatile compared to ATRC. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, AZTA has a market cap of 1.20B. Regarding current trading prices, BDXA is priced at $59.24, while AZTA trades at $26.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas AZTA's P/E ratio is -8.26. In terms of profitability, BDXA's ROE is +0.06%, compared to AZTA's ROE of -0.08%. Regarding short-term risk, BDXA is more volatile compared to AZTA. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, KMTS has a market cap of 1.16B. Regarding current trading prices, BDXA is priced at $59.24, while KMTS trades at $22.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas KMTS's P/E ratio is -11.76. In terms of profitability, BDXA's ROE is +0.06%, compared to KMTS's ROE of N/A. Regarding short-term risk, BDXA is less volatile compared to KMTS. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, BLFS has a market cap of 1.15B. Regarding current trading prices, BDXA is priced at $59.24, while BLFS trades at $24.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas BLFS's P/E ratio is -96.80. In terms of profitability, BDXA's ROE is +0.06%, compared to BLFS's ROE of -0.06%. Regarding short-term risk, BDXA is more volatile compared to BLFS. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, PBHDF has a market cap of 1.12B. Regarding current trading prices, BDXA is priced at $59.24, while PBHDF trades at $19.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas PBHDF's P/E ratio is 12.74. In terms of profitability, BDXA's ROE is +0.06%, compared to PBHDF's ROE of +0.06%. Regarding short-term risk, BDXA is more volatile compared to PBHDF. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, PLSE has a market cap of 1.12B. Regarding current trading prices, BDXA is priced at $59.24, while PLSE trades at $16.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas PLSE's P/E ratio is -18.03. In terms of profitability, BDXA's ROE is +0.06%, compared to PLSE's ROE of -0.83%. Regarding short-term risk, BDXA is more volatile compared to PLSE. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, TDVXF has a market cap of 980.36M. Regarding current trading prices, BDXA is priced at $59.24, while TDVXF trades at $9.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas TDVXF's P/E ratio is 62.33. In terms of profitability, BDXA's ROE is +0.06%, compared to TDVXF's ROE of +0.39%. Regarding short-term risk, BDXA is more volatile compared to TDVXF. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, STAA has a market cap of 940.01M. Regarding current trading prices, BDXA is priced at $59.24, while STAA trades at $18.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas STAA's P/E ratio is -46.29. In terms of profitability, BDXA's ROE is +0.06%, compared to STAA's ROE of -0.05%. Regarding short-term risk, BDXA is more volatile compared to STAA. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, BITGF has a market cap of 910.16M. Regarding current trading prices, BDXA is priced at $59.24, while BITGF trades at $11.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas BITGF's P/E ratio is 34.85. In terms of profitability, BDXA's ROE is +0.06%, compared to BITGF's ROE of +0.06%. Regarding short-term risk, BDXA is less volatile compared to BITGF. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, NNCSF has a market cap of 892.58M. Regarding current trading prices, BDXA is priced at $59.24, while NNCSF trades at $2.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas NNCSF's P/E ratio is 98.00. In terms of profitability, BDXA's ROE is +0.06%, compared to NNCSF's ROE of +0.07%. Regarding short-term risk, BDXA is less volatile compared to NNCSF. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, KSRBF has a market cap of 869.34M. Regarding current trading prices, BDXA is priced at $59.24, while KSRBF trades at $0.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas KSRBF's P/E ratio is 4.87. In terms of profitability, BDXA's ROE is +0.06%, compared to KSRBF's ROE of +0.03%. Regarding short-term risk, BDXA is less volatile compared to KSRBF. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, ATRI has a market cap of 809.44M. Regarding current trading prices, BDXA is priced at $59.24, while ATRI trades at $459.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas ATRI's P/E ratio is 64.50. In terms of profitability, BDXA's ROE is +0.06%, compared to ATRI's ROE of +0.05%. Regarding short-term risk, BDXA is more volatile compared to ATRI. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, SPMXF has a market cap of 550.31M. Regarding current trading prices, BDXA is priced at $59.24, while SPMXF trades at $0.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas SPMXF's P/E ratio is -18.00. In terms of profitability, BDXA's ROE is +0.06%, compared to SPMXF's ROE of -0.05%. Regarding short-term risk, BDXA is more volatile compared to SPMXF. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, JNDOF has a market cap of 531.00M. Regarding current trading prices, BDXA is priced at $59.24, while JNDOF trades at $22.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas JNDOF's P/E ratio is 47.40. In terms of profitability, BDXA's ROE is +0.06%, compared to JNDOF's ROE of +0.20%. Regarding short-term risk, BDXA is more volatile compared to JNDOF. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, HGYMF has a market cap of 524.77M. Regarding current trading prices, BDXA is priced at $59.24, while HGYMF trades at $24.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas HGYMF's P/E ratio is 33.81. In terms of profitability, BDXA's ROE is +0.06%, compared to HGYMF's ROE of +0.02%. Regarding short-term risk, BDXA is more volatile compared to HGYMF. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, SAFLY has a market cap of 449.61M. Regarding current trading prices, BDXA is priced at $59.24, while SAFLY trades at $2.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas SAFLY's P/E ratio is 223.00. In terms of profitability, BDXA's ROE is +0.06%, compared to SAFLY's ROE of +0.00%. Regarding short-term risk, BDXA is less volatile compared to SAFLY. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, ANGO has a market cap of 366.28M. Regarding current trading prices, BDXA is priced at $59.24, while ANGO trades at $9.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas ANGO's P/E ratio is -8.93. In terms of profitability, BDXA's ROE is +0.06%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, BDXA is more volatile compared to ANGO. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, CLHLF has a market cap of 365.45M. Regarding current trading prices, BDXA is priced at $59.24, while CLHLF trades at $61.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas CLHLF's P/E ratio is 27.93. In terms of profitability, BDXA's ROE is +0.06%, compared to CLHLF's ROE of +0.12%. Regarding short-term risk, BDXA is more volatile compared to CLHLF. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, SAFLF has a market cap of 306.46M. Regarding current trading prices, BDXA is priced at $59.24, while SAFLF trades at $0.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas SAFLF's P/E ratio is 12.67. In terms of profitability, BDXA's ROE is +0.06%, compared to SAFLF's ROE of +0.00%. Regarding short-term risk, BDXA is less volatile compared to SAFLF. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, SMTI has a market cap of 287.62M. Regarding current trading prices, BDXA is priced at $59.24, while SMTI trades at $32.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas SMTI's P/E ratio is -28.39. In terms of profitability, BDXA's ROE is +0.06%, compared to SMTI's ROE of -0.24%. Regarding short-term risk, BDXA is more volatile compared to SMTI. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, GUERF has a market cap of 281.03M. Regarding current trading prices, BDXA is priced at $59.24, while GUERF trades at $22.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas GUERF's P/E ratio is 8.19. In terms of profitability, BDXA's ROE is +0.06%, compared to GUERF's ROE of N/A. Regarding short-term risk, BDXA is more volatile compared to GUERF. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, NNNN has a market cap of 277.83M. Regarding current trading prices, BDXA is priced at $59.24, while NNNN trades at $6.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas NNNN's P/E ratio is 126.60. In terms of profitability, BDXA's ROE is +0.06%, compared to NNNN's ROE of N/A. Regarding short-term risk, BDXA is less volatile compared to NNNN. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, TSNLF has a market cap of 252.35M. Regarding current trading prices, BDXA is priced at $59.24, while TSNLF trades at $5.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas TSNLF's P/E ratio is 33.06. In terms of profitability, BDXA's ROE is +0.06%, compared to TSNLF's ROE of +0.21%. Regarding short-term risk, BDXA is more volatile compared to TSNLF. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, OPSSF has a market cap of 247.43M. Regarding current trading prices, BDXA is priced at $59.24, while OPSSF trades at $2.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas OPSSF's P/E ratio is -26.74. In terms of profitability, BDXA's ROE is +0.06%, compared to OPSSF's ROE of -0.17%. Regarding short-term risk, BDXA is more volatile compared to OPSSF. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, NYXH has a market cap of 223.17M. Regarding current trading prices, BDXA is priced at $59.24, while NYXH trades at $6.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas NYXH's P/E ratio is -3.29. In terms of profitability, BDXA's ROE is +0.06%, compared to NYXH's ROE of -0.56%. Regarding short-term risk, BDXA is less volatile compared to NYXH. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, OSUR has a market cap of 220.84M. Regarding current trading prices, BDXA is priced at $59.24, while OSUR trades at $2.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas OSUR's P/E ratio is -10.96. In terms of profitability, BDXA's ROE is +0.06%, compared to OSUR's ROE of -0.05%. Regarding short-term risk, BDXA is more volatile compared to OSUR. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, ZTEK has a market cap of 181.50M. Regarding current trading prices, BDXA is priced at $59.24, while ZTEK trades at $1.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas ZTEK's P/E ratio is -21.75. In terms of profitability, BDXA's ROE is +0.06%, compared to ZTEK's ROE of -0.58%. Regarding short-term risk, BDXA is less volatile compared to ZTEK. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, STXS has a market cap of 171.96M. Regarding current trading prices, BDXA is priced at $59.24, while STXS trades at $2.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas STXS's P/E ratio is -6.67. In terms of profitability, BDXA's ROE is +0.06%, compared to STXS's ROE of -1.49%. Regarding short-term risk, BDXA is more volatile compared to STXS. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, UTMD has a market cap of 171.61M. Regarding current trading prices, BDXA is priced at $59.24, while UTMD trades at $52.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas UTMD's P/E ratio is 13.20. In terms of profitability, BDXA's ROE is +0.06%, compared to UTMD's ROE of +0.11%. Regarding short-term risk, BDXA is more volatile compared to UTMD. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, PDEX has a market cap of 146.55M. Regarding current trading prices, BDXA is priced at $59.24, while PDEX trades at $44.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas PDEX's P/E ratio is 16.28. In terms of profitability, BDXA's ROE is +0.06%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, BDXA is less volatile compared to PDEX. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, KRMD has a market cap of 127.24M. Regarding current trading prices, BDXA is priced at $59.24, while KRMD trades at $2.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas KRMD's P/E ratio is -21.23. In terms of profitability, BDXA's ROE is +0.06%, compared to KRMD's ROE of -0.34%. Regarding short-term risk, BDXA is more volatile compared to KRMD. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, ZJYL has a market cap of 125.24M. Regarding current trading prices, BDXA is priced at $59.24, while ZJYL trades at $0.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas ZJYL's P/E ratio is 40.00. In terms of profitability, BDXA's ROE is +0.06%, compared to ZJYL's ROE of +0.13%. Regarding short-term risk, BDXA is less volatile compared to ZJYL. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, INFU has a market cap of 100.88M. Regarding current trading prices, BDXA is priced at $59.24, while INFU trades at $4.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas INFU's P/E ratio is 43.64. In terms of profitability, BDXA's ROE is +0.06%, compared to INFU's ROE of +0.04%. Regarding short-term risk, BDXA is more volatile compared to INFU. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, MBOT has a market cap of 86.86M. Regarding current trading prices, BDXA is priced at $59.24, while MBOT trades at $2.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas MBOT's P/E ratio is -3.42. In terms of profitability, BDXA's ROE is +0.06%, compared to MBOT's ROE of -2.34%. Regarding short-term risk, BDXA is less volatile compared to MBOT. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, MLSS has a market cap of 79.94M. Regarding current trading prices, BDXA is priced at $59.24, while MLSS trades at $1.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas MLSS's P/E ratio is -17.00. In terms of profitability, BDXA's ROE is +0.06%, compared to MLSS's ROE of -0.66%. Regarding short-term risk, BDXA is less volatile compared to MLSS. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, EEOIF has a market cap of 63.38M. Regarding current trading prices, BDXA is priced at $59.24, while EEOIF trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas EEOIF's P/E ratio is -2.42. In terms of profitability, BDXA's ROE is +0.06%, compared to EEOIF's ROE of N/A. Regarding short-term risk, BDXA is more volatile compared to EEOIF. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, AKYA has a market cap of 62.34M. Regarding current trading prices, BDXA is priced at $59.24, while AKYA trades at $1.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas AKYA's P/E ratio is -1.12. In terms of profitability, BDXA's ROE is +0.06%, compared to AKYA's ROE of -2.91%. Regarding short-term risk, BDXA is less volatile compared to AKYA. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, UEEC has a market cap of 56.79M. Regarding current trading prices, BDXA is priced at $59.24, while UEEC trades at $0.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas UEEC's P/E ratio is -22.50. In terms of profitability, BDXA's ROE is +0.06%, compared to UEEC's ROE of +0.96%. Regarding short-term risk, BDXA is less volatile compared to UEEC. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, OMIC has a market cap of 50.77M. Regarding current trading prices, BDXA is priced at $59.24, while OMIC trades at $20.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas OMIC's P/E ratio is -0.58. In terms of profitability, BDXA's ROE is +0.06%, compared to OMIC's ROE of -0.58%. Regarding short-term risk, BDXA is more volatile compared to OMIC. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, IGAP has a market cap of 50.23M. Regarding current trading prices, BDXA is priced at $59.24, while IGAP trades at $3.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas IGAP's P/E ratio is -10.52. In terms of profitability, BDXA's ROE is +0.06%, compared to IGAP's ROE of +4.55%. Regarding short-term risk, BDXA is more volatile compared to IGAP. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, DXR has a market cap of 34.91M. Regarding current trading prices, BDXA is priced at $59.24, while DXR trades at $7.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas DXR's P/E ratio is -80.19. In terms of profitability, BDXA's ROE is +0.06%, compared to DXR's ROE of +0.02%. Regarding short-term risk, BDXA is less volatile compared to DXR. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, POCI has a market cap of 32.05M. Regarding current trading prices, BDXA is priced at $59.24, while POCI trades at $4.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas POCI's P/E ratio is -6.43. In terms of profitability, BDXA's ROE is +0.06%, compared to POCI's ROE of -0.39%. Regarding short-term risk, BDXA is more volatile compared to POCI. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, FEMY has a market cap of 32.04M. Regarding current trading prices, BDXA is priced at $59.24, while FEMY trades at $1.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas FEMY's P/E ratio is -1.39. In terms of profitability, BDXA's ROE is +0.06%, compared to FEMY's ROE of -2.14%. Regarding short-term risk, BDXA is less volatile compared to FEMY. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, SDC has a market cap of 29.11M. Regarding current trading prices, BDXA is priced at $59.24, while SDC trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas SDC's P/E ratio is -0.03. In terms of profitability, BDXA's ROE is +0.06%, compared to SDC's ROE of -1.96%. Regarding short-term risk, BDXA is less volatile compared to SDC. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, NXGLW has a market cap of 27.24M. Regarding current trading prices, BDXA is priced at $59.24, while NXGLW trades at $0.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas NXGLW's P/E ratio is -0.29. In terms of profitability, BDXA's ROE is +0.06%, compared to NXGLW's ROE of -0.68%. Regarding short-term risk, BDXA is more volatile compared to NXGLW. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, IVC has a market cap of 24.91M. Regarding current trading prices, BDXA is priced at $59.24, while IVC trades at $0.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas IVC's P/E ratio is -0.79. In terms of profitability, BDXA's ROE is +0.06%, compared to IVC's ROE of -0.46%. Regarding short-term risk, BDXA is less volatile compared to IVC. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, RVP has a market cap of 22.69M. Regarding current trading prices, BDXA is priced at $59.24, while RVP trades at $0.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas RVP's P/E ratio is -1.89. In terms of profitability, BDXA's ROE is +0.06%, compared to RVP's ROE of -0.13%. Regarding short-term risk, BDXA is less volatile compared to RVP. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, IMTH has a market cap of 21.53M. Regarding current trading prices, BDXA is priced at $59.24, while IMTH trades at $0.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas IMTH's P/E ratio is -1.05. In terms of profitability, BDXA's ROE is +0.06%, compared to IMTH's ROE of +2.29%. Regarding short-term risk, BDXA is more volatile compared to IMTH. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, NXGL has a market cap of 19.90M. Regarding current trading prices, BDXA is priced at $59.24, while NXGL trades at $2.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas NXGL's P/E ratio is -5.20. In terms of profitability, BDXA's ROE is +0.06%, compared to NXGL's ROE of -0.68%. Regarding short-term risk, BDXA is more volatile compared to NXGL. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, NEPH has a market cap of 19.61M. Regarding current trading prices, BDXA is priced at $59.24, while NEPH trades at $1.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas NEPH's P/E ratio is 185.00. In terms of profitability, BDXA's ROE is +0.06%, compared to NEPH's ROE of +0.01%. Regarding short-term risk, BDXA is more volatile compared to NEPH. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, GVDI has a market cap of 16.21M. Regarding current trading prices, BDXA is priced at $59.24, while GVDI trades at $0.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas GVDI's P/E ratio is N/A. In terms of profitability, BDXA's ROE is +0.06%, compared to GVDI's ROE of +0.00%. Regarding short-term risk, BDXA is less volatile compared to GVDI. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, HBIO has a market cap of 14.59M. Regarding current trading prices, BDXA is priced at $59.24, while HBIO trades at $0.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas HBIO's P/E ratio is -1.18. In terms of profitability, BDXA's ROE is +0.06%, compared to HBIO's ROE of -0.19%. Regarding short-term risk, BDXA is less volatile compared to HBIO. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, LUCYW has a market cap of 13.82M. Regarding current trading prices, BDXA is priced at $59.24, while LUCYW trades at $0.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas LUCYW's P/E ratio is N/A. In terms of profitability, BDXA's ROE is +0.06%, compared to LUCYW's ROE of -0.99%. Regarding short-term risk, BDXA is less volatile compared to LUCYW. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, EKSO has a market cap of 13.42M. Regarding current trading prices, BDXA is priced at $59.24, while EKSO trades at $0.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas EKSO's P/E ratio is -0.83. In terms of profitability, BDXA's ROE is +0.06%, compared to EKSO's ROE of -0.84%. Regarding short-term risk, BDXA is less volatile compared to EKSO. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, YBGJ has a market cap of 10.66M. Regarding current trading prices, BDXA is priced at $59.24, while YBGJ trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas YBGJ's P/E ratio is -4.45. In terms of profitability, BDXA's ROE is +0.06%, compared to YBGJ's ROE of +3.46%. Regarding short-term risk, BDXA is more volatile compared to YBGJ. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, POAI has a market cap of 9.56M. Regarding current trading prices, BDXA is priced at $59.24, while POAI trades at $1.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas POAI's P/E ratio is -0.54. In terms of profitability, BDXA's ROE is +0.06%, compared to POAI's ROE of -5.11%. Regarding short-term risk, BDXA is more volatile compared to POAI. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, OTCFF has a market cap of 8.63M. Regarding current trading prices, BDXA is priced at $59.24, while OTCFF trades at $0.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas OTCFF's P/E ratio is -10.00. In terms of profitability, BDXA's ROE is +0.06%, compared to OTCFF's ROE of +18.74%. Regarding short-term risk, BDXA is more volatile compared to OTCFF. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, TEVNF has a market cap of 7.52M. Regarding current trading prices, BDXA is priced at $59.24, while TEVNF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas TEVNF's P/E ratio is N/A. In terms of profitability, BDXA's ROE is +0.06%, compared to TEVNF's ROE of +3.22%. Regarding short-term risk, BDXA is less volatile compared to TEVNF. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, MHUA has a market cap of 6.84M. Regarding current trading prices, BDXA is priced at $59.24, while MHUA trades at $0.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas MHUA's P/E ratio is 0.66. In terms of profitability, BDXA's ROE is +0.06%, compared to MHUA's ROE of +0.09%. Regarding short-term risk, BDXA is less volatile compared to MHUA. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, WOK has a market cap of 6.81M. Regarding current trading prices, BDXA is priced at $59.24, while WOK trades at $0.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas WOK's P/E ratio is -1.73. In terms of profitability, BDXA's ROE is +0.06%, compared to WOK's ROE of N/A. Regarding short-term risk, BDXA is less volatile compared to WOK. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, BLMHF has a market cap of 5.22M. Regarding current trading prices, BDXA is priced at $59.24, while BLMHF trades at $0.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas BLMHF's P/E ratio is 1.56. In terms of profitability, BDXA's ROE is +0.06%, compared to BLMHF's ROE of N/A. Regarding short-term risk, BDXA is more volatile compared to BLMHF. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, NSTG has a market cap of 5.07M. Regarding current trading prices, BDXA is priced at $59.24, while NSTG trades at $0.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas NSTG's P/E ratio is -0.03. In terms of profitability, BDXA's ROE is +0.06%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, BDXA is less volatile compared to NSTG. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, ECIA has a market cap of 4.99M. Regarding current trading prices, BDXA is priced at $59.24, while ECIA trades at $0.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas ECIA's P/E ratio is -10.50. In terms of profitability, BDXA's ROE is +0.06%, compared to ECIA's ROE of -0.33%. Regarding short-term risk, BDXA is less volatile compared to ECIA. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, GCTK has a market cap of 4.72M. Regarding current trading prices, BDXA is priced at $59.24, while GCTK trades at $0.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas GCTK's P/E ratio is N/A. In terms of profitability, BDXA's ROE is +0.06%, compared to GCTK's ROE of +4.55%. Regarding short-term risk, BDXA is less volatile compared to GCTK. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, LUCY has a market cap of 4.66M. Regarding current trading prices, BDXA is priced at $59.24, while LUCY trades at $1.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas LUCY's P/E ratio is -0.37. In terms of profitability, BDXA's ROE is +0.06%, compared to LUCY's ROE of -0.99%. Regarding short-term risk, BDXA is more volatile compared to LUCY. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, PXMVF has a market cap of 4.62M. Regarding current trading prices, BDXA is priced at $59.24, while PXMVF trades at $1.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas PXMVF's P/E ratio is -0.17. In terms of profitability, BDXA's ROE is +0.06%, compared to PXMVF's ROE of N/A. Regarding short-term risk, BDXA is less volatile compared to PXMVF. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, MCDA has a market cap of 4.24M. Regarding current trading prices, BDXA is priced at $59.24, while MCDA trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas MCDA's P/E ratio is N/A. In terms of profitability, BDXA's ROE is +0.06%, compared to MCDA's ROE of N/A. Regarding short-term risk, BDXA is more volatile compared to MCDA. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, CBSC has a market cap of 3.74M. Regarding current trading prices, BDXA is priced at $59.24, while CBSC trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas CBSC's P/E ratio is -3.32. In terms of profitability, BDXA's ROE is +0.06%, compared to CBSC's ROE of +1.52%. Regarding short-term risk, BDXA is more volatile compared to CBSC. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, RSCF has a market cap of 3.38M. Regarding current trading prices, BDXA is priced at $59.24, while RSCF trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas RSCF's P/E ratio is -3.94. In terms of profitability, BDXA's ROE is +0.06%, compared to RSCF's ROE of +0.08%. Regarding short-term risk, BDXA is more volatile compared to RSCF. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, NSTGQ has a market cap of 3.31M. Regarding current trading prices, BDXA is priced at $59.24, while NSTGQ trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas NSTGQ's P/E ratio is N/A. In terms of profitability, BDXA's ROE is +0.06%, compared to NSTGQ's ROE of N/A. Regarding short-term risk, BDXA is more volatile compared to NSTGQ. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, GMVD has a market cap of 1.80M. Regarding current trading prices, BDXA is priced at $59.24, while GMVD trades at $0.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas GMVD's P/E ratio is -0.01. In terms of profitability, BDXA's ROE is +0.06%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, BDXA is less volatile compared to GMVD. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, GMVDW has a market cap of 1.80M. Regarding current trading prices, BDXA is priced at $59.24, while GMVDW trades at $7.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas GMVDW's P/E ratio is N/A. In terms of profitability, BDXA's ROE is +0.06%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, BDXA is less volatile compared to GMVDW. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, AVGR has a market cap of 1.52M. Regarding current trading prices, BDXA is priced at $59.24, while AVGR trades at $0.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas AVGR's P/E ratio is -0.05. In terms of profitability, BDXA's ROE is +0.06%, compared to AVGR's ROE of -54.25%. Regarding short-term risk, BDXA is less volatile compared to AVGR. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, OJSY has a market cap of 454285.00. Regarding current trading prices, BDXA is priced at $59.24, while OJSY trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas OJSY's P/E ratio is N/A. In terms of profitability, BDXA's ROE is +0.06%, compared to OJSY's ROE of N/A. Regarding short-term risk, BDXA is more volatile compared to OJSY. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, REMI has a market cap of 399920.00. Regarding current trading prices, BDXA is priced at $59.24, while REMI trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas REMI's P/E ratio is -2.00. In terms of profitability, BDXA's ROE is +0.06%, compared to REMI's ROE of -0.08%. Regarding short-term risk, BDXA is less volatile compared to REMI. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, PDMI has a market cap of 324879.00. Regarding current trading prices, BDXA is priced at $59.24, while PDMI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas PDMI's P/E ratio is -0.01. In terms of profitability, BDXA's ROE is +0.06%, compared to PDMI's ROE of +0.19%. Regarding short-term risk, BDXA is more volatile compared to PDMI. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, STSS has a market cap of 253174.00. Regarding current trading prices, BDXA is priced at $59.24, while STSS trades at $4.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas STSS's P/E ratio is N/A. In terms of profitability, BDXA's ROE is +0.06%, compared to STSS's ROE of -1.65%. Regarding short-term risk, BDXA is less volatile compared to STSS. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, WHSI has a market cap of 182671.00. Regarding current trading prices, BDXA is priced at $59.24, while WHSI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas WHSI's P/E ratio is N/A. In terms of profitability, BDXA's ROE is +0.06%, compared to WHSI's ROE of +0.84%. Regarding short-term risk, BDXA is more volatile compared to WHSI. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, BLFE has a market cap of 156683.00. Regarding current trading prices, BDXA is priced at $59.24, while BLFE trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas BLFE's P/E ratio is N/A. In terms of profitability, BDXA's ROE is +0.06%, compared to BLFE's ROE of +0.00%. Regarding short-term risk, BDXA is less volatile compared to BLFE. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, QTXB has a market cap of 118045.00. Regarding current trading prices, BDXA is priced at $59.24, while QTXB trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas QTXB's P/E ratio is -0.05. In terms of profitability, BDXA's ROE is +0.06%, compared to QTXB's ROE of +0.00%. Regarding short-term risk, BDXA is less volatile compared to QTXB. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, CEOS has a market cap of 102944.00. Regarding current trading prices, BDXA is priced at $59.24, while CEOS trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas CEOS's P/E ratio is N/A. In terms of profitability, BDXA's ROE is +0.06%, compared to CEOS's ROE of +1.18%. Regarding short-term risk, BDXA is less volatile compared to CEOS. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, GMVDF has a market cap of 51984.00. Regarding current trading prices, BDXA is priced at $59.24, while GMVDF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas GMVDF's P/E ratio is N/A. In terms of profitability, BDXA's ROE is +0.06%, compared to GMVDF's ROE of N/A. Regarding short-term risk, BDXA is more volatile compared to GMVDF. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, LANZ has a market cap of 27690.00. Regarding current trading prices, BDXA is priced at $59.24, while LANZ trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas LANZ's P/E ratio is 1.00. In terms of profitability, BDXA's ROE is +0.06%, compared to LANZ's ROE of N/A. Regarding short-term risk, BDXA is more volatile compared to LANZ. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, INND has a market cap of 22401.00. Regarding current trading prices, BDXA is priced at $59.24, while INND trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas INND's P/E ratio is N/A. In terms of profitability, BDXA's ROE is +0.06%, compared to INND's ROE of +0.32%. Regarding short-term risk, BDXA is less volatile compared to INND. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, ASFX has a market cap of 17502.00. Regarding current trading prices, BDXA is priced at $59.24, while ASFX trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas ASFX's P/E ratio is N/A. In terms of profitability, BDXA's ROE is +0.06%, compared to ASFX's ROE of +0.00%. Regarding short-term risk, BDXA is more volatile compared to ASFX. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, MDIT has a market cap of 8620.00. Regarding current trading prices, BDXA is priced at $59.24, while MDIT trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas MDIT's P/E ratio is N/A. In terms of profitability, BDXA's ROE is +0.06%, compared to MDIT's ROE of -0.99%. Regarding short-term risk, BDXA is more volatile compared to MDIT. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, SDCCQ has a market cap of 4030.00. Regarding current trading prices, BDXA is priced at $59.24, while SDCCQ trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas SDCCQ's P/E ratio is N/A. In terms of profitability, BDXA's ROE is +0.06%, compared to SDCCQ's ROE of -0.61%. Regarding short-term risk, BDXA is less volatile compared to SDCCQ. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, DGEN has a market cap of 3859.00. Regarding current trading prices, BDXA is priced at $59.24, while DGEN trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas DGEN's P/E ratio is N/A. In terms of profitability, BDXA's ROE is +0.06%, compared to DGEN's ROE of N/A. Regarding short-term risk, BDXA is more volatile compared to DGEN. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, LFPI has a market cap of 2042.00. Regarding current trading prices, BDXA is priced at $59.24, while LFPI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas LFPI's P/E ratio is N/A. In terms of profitability, BDXA's ROE is +0.06%, compared to LFPI's ROE of -4.85%. Regarding short-term risk, BDXA is less volatile compared to LFPI. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, SVSO has a market cap of 1276.00. Regarding current trading prices, BDXA is priced at $59.24, while SVSO trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas SVSO's P/E ratio is N/A. In terms of profitability, BDXA's ROE is +0.06%, compared to SVSO's ROE of +0.17%. Regarding short-term risk, BDXA is less volatile compared to SVSO. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, SEYE has a market cap of 1159.00. Regarding current trading prices, BDXA is priced at $59.24, while SEYE trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas SEYE's P/E ratio is N/A. In terms of profitability, BDXA's ROE is +0.06%, compared to SEYE's ROE of N/A. Regarding short-term risk, BDXA is more volatile compared to SEYE. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, BGMD has a market cap of 1137.00. Regarding current trading prices, BDXA is priced at $59.24, while BGMD trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas BGMD's P/E ratio is N/A. In terms of profitability, BDXA's ROE is +0.06%, compared to BGMD's ROE of +0.00%. Regarding short-term risk, BDXA is less volatile compared to BGMD. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, ADLI has a market cap of 1039.00. Regarding current trading prices, BDXA is priced at $59.24, while ADLI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas ADLI's P/E ratio is N/A. In terms of profitability, BDXA's ROE is +0.06%, compared to ADLI's ROE of +1.36%. Regarding short-term risk, BDXA is less volatile compared to ADLI. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, VSMD has a market cap of 801.00. Regarding current trading prices, BDXA is priced at $59.24, while VSMD trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas VSMD's P/E ratio is N/A. In terms of profitability, BDXA's ROE is +0.06%, compared to VSMD's ROE of +3.15%. Regarding short-term risk, BDXA is less volatile compared to VSMD. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, HRAL has a market cap of 446.00. Regarding current trading prices, BDXA is priced at $59.24, while HRAL trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas HRAL's P/E ratio is N/A. In terms of profitability, BDXA's ROE is +0.06%, compared to HRAL's ROE of +0.13%. Regarding short-term risk, BDXA is less volatile compared to HRAL. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, MICRD has a market cap of 291.00. Regarding current trading prices, BDXA is priced at $59.24, while MICRD trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas MICRD's P/E ratio is N/A. In terms of profitability, BDXA's ROE is +0.06%, compared to MICRD's ROE of -0.25%. Regarding short-term risk, BDXA is more volatile compared to MICRD. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, RGBOQ has a market cap of 97.00. Regarding current trading prices, BDXA is priced at $59.24, while RGBOQ trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas RGBOQ's P/E ratio is -0.00. In terms of profitability, BDXA's ROE is +0.06%, compared to RGBOQ's ROE of N/A. Regarding short-term risk, BDXA is more volatile compared to RGBOQ. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, SECI has a market cap of 31.00. Regarding current trading prices, BDXA is priced at $59.24, while SECI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas SECI's P/E ratio is N/A. In terms of profitability, BDXA's ROE is +0.06%, compared to SECI's ROE of -0.00%. Regarding short-term risk, BDXA is more volatile compared to SECI. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, VTEQ has a market cap of 1.00. Regarding current trading prices, BDXA is priced at $59.24, while VTEQ trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas VTEQ's P/E ratio is -0.00. In terms of profitability, BDXA's ROE is +0.06%, compared to VTEQ's ROE of N/A. Regarding short-term risk, BDXA is more volatile compared to VTEQ. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, APR comparison data is unavailable. Regarding current trading prices, BDXA is priced at $59.24, while APR trades at $37.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas APR's P/E ratio is 22.59. In terms of profitability, BDXA's ROE is +0.06%, compared to APR's ROE of +9.81%. Regarding short-term risk, BDXA is more volatile compared to APR. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, LMNX comparison data is unavailable. Regarding current trading prices, BDXA is priced at $59.24, while LMNX trades at $36.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas LMNX's P/E ratio is N/A. In terms of profitability, BDXA's ROE is +0.06%, compared to LMNX's ROE of +0.03%. Regarding short-term risk, BDXA is more volatile compared to LMNX. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, ATRS comparison data is unavailable. Regarding current trading prices, BDXA is priced at $59.24, while ATRS trades at $5.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas ATRS's P/E ratio is 14.95. In terms of profitability, BDXA's ROE is +0.06%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, BDXA is more volatile compared to ATRS. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, OCPNY comparison data is unavailable. Regarding current trading prices, BDXA is priced at $59.24, while OCPNY trades at $18.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas OCPNY's P/E ratio is N/A. In terms of profitability, BDXA's ROE is +0.06%, compared to OCPNY's ROE of +0.26%. Regarding short-term risk, BDXA is more volatile compared to OCPNY. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, HRC comparison data is unavailable. Regarding current trading prices, BDXA is priced at $59.24, while HRC trades at $155.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas HRC's P/E ratio is 41.92. In terms of profitability, BDXA's ROE is +0.06%, compared to HRC's ROE of +0.14%. Regarding short-term risk, BDXA is more volatile compared to HRC. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.

BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDXA stands at 58.89B. In comparison, IIN comparison data is unavailable. Regarding current trading prices, BDXA is priced at $59.24, while IIN trades at $24.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDXA currently has a P/E ratio of 21.44, whereas IIN's P/E ratio is 226.45. In terms of profitability, BDXA's ROE is +0.06%, compared to IIN's ROE of -0.00%. Regarding short-term risk, BDXA is more volatile compared to IIN. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.